FTH Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
22.1M
+20.1%
18.4M
R&D
11.7M
+27.8%
9.2M
SG&A
10.3M
+12.4%
9.2M
Operating Income
-22086000
-20.1%
-18385000
EBITDA
-22069000
-20.2%
-18360000
Net Income
-20398000
-27.4%
-16007000
EPS (Basic)
$-0.79
+72.2%
$-2.84
EPS (Diluted)
$-0.79
+72.2%
$-2.84
Shares (Diluted)
25.8M
+357.9%
5.6M
Faeth Therapeutics (FTH) — Financials